Completed PHASE4 INTERVENTIONAL 1-arm NCT02072408

Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

Sponsor: Bayer

Conditions Polypoidal Choroidal Vasculopathy Without Active Polyp

Interventions aflibercept

Updated 7 times since 2017 Last updated: Sep 2, 2018 Started: Feb 28, 2014 Primary completion: Nov 2, 2017 Completion: Nov 2, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02072408, this PHASE4 trial focuses on Polypoidal Choroidal Vasculopathy Without Active Polyp and remains completed. Sponsored by Bayer, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Oct 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Jun 2018 — Oct 2018 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Kim's Eye Hospital
Samsung Medical Center
Seoul National University Bundang Hospital

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seongnam, South Korea
• Seoul, South Korea